Newly approved medication sotagliflozin significantly reduces heart attacks and strokes in patients with type 2 diabetes, kidney disease, and cardiovascular risk factors. The drug, an SGLT inhibitor, blocks glucose and sodium transport across cell membranes to control blood sugar levels.
A recent study published in The Lancet Diabetes & Endocrinology found that sotagliflozin reduces the rate of heart attacks, strokes, and deaths from these cardiovascular causes by 23% compared to a placebo. Researchers enrolled 10,584 patients and followed them for an average of 16 months.
The results are significant because they show a unique mechanism of action for SGLT inhibitors, which sets sotagliflozin apart from other treatments. This means that sotagliflozin could become a widely used option to reduce global cardiovascular risk in patients with heart failure or type 2 diabetes.
Sotagliflozin was approved by the FDA to reduce cardiovascular risk, but these new data demonstrate its additional benefits in reducing heart attacks and strokes. Dr. Deepak L. Bhatt, study chair, notes that physicians now have a new option to manage global cardiovascular risk and improve patient outcomes.
Source: https://medicalxpress.com/news/2025-02-sotagliflozin-medication-kind-significantly-heart.html